AMAG Pharmaceuticals, Inc. announced earnings results for the fourth quarter ended December 31, 2019. For the fourth quarter, the company announced total revenue was USD 89.709 million compared to USD 88.122 million a year ago. Operating loss was USD 193.940 million compared to USD 18.835 million a year ago. Net loss was USD 199.927 million compared to USD 22.277 million a year ago. Basic loss per share was USD 5.89 compared to USD 0.64 a year ago. Basic loss per share from continuing operations was USD 5.89 compared to USD 0.6 a year ago. For the full year, total revenue was USD 327.751 million compared to USD 474.002 million a year ago. Operating loss was USD 445.507 million compared to USD 47.046 million a year ago. Net loss was USD 466.456 million compared to USD 65.761 million a year ago. Basic loss per share was USD 13.71 compared to USD 1.91 a year ago. Basic loss per share from continuing operations was USD 13.71 compared to USD 4.92 a year ago.